CTLA4 and cancer: For example, immune checkpoint inhibitors based on monoclonal antibodies targeting PD-1 or cytotoxic T-lymphocyte antigen 4 (CTLA-4) have shown impressive results in the treatment of several types of cancer, but limited benefits so far in GB patients, which is mainly believed to be due to drug resistance [11].